KalVista Pharma (KALV) Stock Forecast & Price Target

KalVista Pharmaceuticals Inc. is positioned for growth with its oral plasma kallikrein inhibitor, sebetralstat, which presents a favorable alternative to existing on-demand therapies for hereditary angioedema (HAE), as indicated by physician surveys reflecting strong enthusiasm for increased patient compliance and treatment initiation. The company anticipates reaching approximately $400 million in worldwide sales at peak, supported by the positive reception of new efficacy data presented at recent conferences, particularly highlighting sebetralstat's effectiveness among adolescents. Despite expected increases in operating expenses, the forthcoming approval of sebetralstat and its potential for rapid adoption in the market contribute to a positive financial outlook for KalVista.

KalVista Pharmaceuticals Inc. reported a net loss of $44.3 million or $0.92 per share for the fiscal third quarter ending January 31, 2025, indicating significant financial strain as the company is likely to continue incurring losses throughout the early phases of its product sebetralstat. The outlook highlights substantial risks, including the potential failure of sebetralstat and lack of alternative pipeline options, which may impede future growth and raise concerns over securing necessary capital for ongoing operations and development. Additionally, regulatory uncertainties surrounding FDA approval and the complexities of commercialization for sebetralstat, particularly as an oral on-demand treatment, further jeopardize the company's financial stability.